G Houston Hall

G. Houston Hall is a Dallas-based investor best documented as co-founder and manager of Falcon Fund, Ltd., a long-short equity hedge fund launched in 1990. USA Water Polo described Falcon Fund as investing in a wide range of securities and businesses, with a strong focus on U.S. publicly traded equities; since 2007, it has operated exclusively as a family-office investment partnership.

Hall is also co-founder of BioMatrix Partners, Ltd., described by USA Water Polo as a family-owned investment partnership focused on public and private biotechnology companies, with an emphasis on early-stage opportunities. SEC filings for Tvardi Therapeutics identify George Houston Hall and Wallace Hall as general partners of BioMatrix Partners Ltd. and list the firm’s address as 5956 Sherry Lane, Suite 1810, Dallas, Texas 75225.

In biotechnology operating roles, Hall co-founded Agilis Biotherapeutics and served as its Managing Director and Executive Chairman. Agilis was built around DNA-based therapeutics and gene therapy programs for severe rare diseases, including central nervous system disorders. PTC Therapeutics completed its acquisition of Agilis on August 23, 2018, adding Agilis’s AADC deficiency gene therapy program and other rare-disease gene therapy assets.

Hall earned an A.B. in Economics from Harvard College in 1982. Outside investing, he has served on the USA Water Polo Board of Directors and has been active in the Dallas Water Polo Club and junior water polo development in North Texas.

• BioMatrix Partners is focused on “public and private biotechnology companies, with an emphasis on early-stage opportunities,” according to USA Water Polo’s board biography of Hall.
• Agilis’s company thesis centered on first-in-class DNA-based therapeutics for life-threatening or fatal rare diseases where treatment options were limited or unavailable.
• Hall’s own Agilis comments emphasized developing “life changing medicines” and advancing rare-disease programs through collaboration with Intrexon’s synthetic-biology platform.
• Documented sector pattern: rare genetic disease, CNS disorders, gene therapy, synthetic biology, Alzheimer’s disease, STAT3-targeted therapies, and other biotech opportunities.
• The Falcon Fund side of his investing background is broader and public-market oriented, with a long-short equity strategy and focus on U.S. publicly traded equities.